|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Zynerba_Pharmaceuticals
|
|
gptkbp:annual_report
|
published yearly
|
|
gptkbp:awards
|
Best Workplaces
|
|
gptkbp:ceo
|
gptkb:Lars_Fruergaard_Jørgensen
|
|
gptkbp:clinical_trial
|
ongoing
diabetes treatment
obesity treatment
hemophilia treatment
growth hormone treatment
|
|
gptkbp:collaborations
|
various universities
|
|
gptkbp:community_engagement
|
health initiatives
|
|
gptkbp:conducts_research_on
|
Mads Krogsgaard Thomsen
|
|
gptkbp:employees
|
approximately 45,000
|
|
gptkbp:focus
|
diabetes care
growth hormone therapy
obesity care
hemophilia care
|
|
gptkbp:founded
|
1923
|
|
gptkbp:founder
|
gptkb:August_Krogh
|
|
gptkbp:global_presence
|
over 80 countries
|
|
gptkbp:has_diversity_initiatives
|
active
|
|
gptkbp:has_research_center
|
multiple locations
|
|
gptkbp:headquarters
|
gptkb:Bagsværd,_Denmark
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NOVO B
|
|
gptkbp:industry
|
healthcare
|
|
gptkbp:innovation
|
gptkb:biotechnology
|
|
gptkbp:invention
|
numerous
|
|
gptkbp:investment
|
R& D
|
|
gptkbp:market
|
global
|
|
gptkbp:market_cap
|
approximately 150 billion USD
|
|
gptkbp:market_leader
|
insulin products
GLP-1 products
|
|
gptkbp:partnership
|
gptkb:University_of_Copenhagen
Danish Diabetes Association
|
|
gptkbp:philanthropy
|
gptkb:Novo_Nordisk_Foundation
|
|
gptkbp:products
|
gptkb:diabetes
GLP-1 receptor agonists
|
|
gptkbp:provides_guidance_on
|
influential
|
|
gptkbp:research
|
biopharmaceuticals
|
|
gptkbp:revenue
|
approximately 20 billion USD
|
|
gptkbp:social_responsibility
|
active
|
|
gptkbp:stock_exchange
|
gptkb:Copenhagen_Stock_Exchange
|
|
gptkbp:stock_symbol
|
NOVO-B
|
|
gptkbp:subsidiaries
|
gptkb:Novo_Nordisk_A/_S
|
|
gptkbp:supply_chain
|
global network
|
|
gptkbp:sustainability
|
social responsibility
environmental responsibility
economic responsibility
|
|
gptkbp:training
|
ongoing
|
|
gptkbp:website
|
novonordisk.com
|
|
gptkbp:bfsParent
|
gptkb:Novo_Nordisk_A/_S
|
|
gptkbp:bfsLayer
|
7
|